-
Press ReleasesMEDIA INQUIRIES Media@BriiBio.com
-
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
October 19, 2022
Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated
Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development
Additional data presented by Brii’s licensing partners at IDWeek 2022 showcase breadth of Company’s infectious disease program, spanning six therapeutic candidates and four potential disease indications -
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
September 26, 2022
Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects
Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people with PPD in an outpatient setting
Company has identified an optimal dose regimen for BRII-296 for the upcoming Phase 2 study expected to commence by end of 2022 -
Brii Biosciences Announces China Leadership Team Changes
September 02, 2022
Dr. Qing Zhu to become China R&D Head, Dr. Ankang Li to join the Board, Mr. Rico Liang to become China GM, and Mr. Yongqing (Rogers) Luo resigned from the Board and his current positions
-
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
September 01, 2022
Addition increases diversity of Board governance and supports further independent expertise
-
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
August 24, 2022
Additions to executive team strengthen global leadership and position Company for strategic long-term growth
First-ever product launch of long-acting amubarvimab/romlusevimab combination therapy for COVID-19 in China advances Brii Bio from clinical development to commercial stage biotechnology company
On track to advance clinical programs in HBV, CNS, HIV and MDR/XDR, and deliver key data read-outs in 2022
Ample funds to support operations through 2025
Company to host conference call today at 8:30 PM HKT / 8:30 AM ET -
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
August 23, 2022
Building a leadership team with global and local experience and expertise to enable rapid execution across Company’s broad therapeutic strategy
-
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA
July 27, 2022
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date
The amubarvimab/romlusevimab combination is commercially available in China and is under review for Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) -
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination,
July 19, 2022
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, evaluated through a randomized, double-blind, placebo-controlled trial
The amubarvimab/romlusevimab combination was commercially launched in China on July 7, 2022 -
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
July 13, 2022
Strategic executive hire adds to Company’s global leadership team and positions the Company for continued growth
-
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
July 07, 2022
The Company is working closely with its commercial partners to supply the combination therapy to patients in need
Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in less than 20 months, validating the Company’s R&D expertise and capabilities -
Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
July 04, 2022
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company’s leadership and robust clinical pipeline in HBV
Key partnership with Vir enables multitude of combination treatment options as part of Company’s strategic approach to developing a functional cure for HBV -
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
June 09, 2022
Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections in China
Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resolution of COVID-19 symptoms, and risk of progressing to severe disease -
Brii Biosciences to be Added to MSCI China Small Cap Index
May 25, 2022
DURHAM, N.C., United States and BEIJING, China – May 25 […]
-
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
May 09, 2022
Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant
Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization -
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
May 07, 2022
DURHAM, N.C., United States and BEIJING, China – May 7, […]
-
Brii Biosciences Announces Upcoming Participation at May Conference
April 29, 2022
DURHAM, N.C., United States and BEIJING, China – April […]
-
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
March 31, 2022
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAg observed in the Chinese patients infected with chronic hepatitis B
-
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
March 30, 2022
The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab combination
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial
National Health Commission of China recently added the amubarvimab/romlusevimab combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) -
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
March 23, 2022
– Advancing key programs in HBV, CNS, and HIV
– Received first BLA approval for COVID-19 Treatment in China and added to China’s latest COVID-19 Diagnosis and Treatment Guidelines
– Multiple clinical value drivers expected across the portfolio in 2022 and beyond
– Cash, bank balances, and potential revenue to support operations through 2025
– Brii Bio to host conference call today at 8:00 PM HKT / 8:00 AM ET -
Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
March 16, 2022
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, through a randomized, double-blind and placebo-controlled trial
In vitro tests shows that amubarvimab/romlusevimab combination retains neutralizing activity against the Omicron variant and other variants of concern such as Delta and Delta Plus -
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
January 27, 2022
Senior hire strengthens Brii Bio’s leadership team and aligns with Company’s mission to tackle the world’s largest public health issues affecting everyday people
